P.MccoyR
Prostate-specific antigen, prostate volume, nocturnal penile tumescence, total and free testosterone, prolactin, luteinizing hormone, erectile function scores, depression, fatigue and other parameters were assessed before treatment, at three months, and after the treatment period
[18] [19] Treatment typically involves a combination of non-pharmacological and pharmacological interventions, tailored to the individual's age, symptom severity, and personal circumstances
The primary endpoint of weight loss of at least 5% occurred in 85% of the tirzepatide 5 mg group, 89% of the tirzepatide 10 mg group and 91% of participants in the tirzepatide 15 mg group